CRISPR Therapeutics AG CRSP

About CRISPR Therapeutics AG (CRSP): stock profile, AI score and financials

CRISPR Therapeutics AG (CRSP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRSP at 5.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,917 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.4) and profitability (0.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CRISPR Therapeutics AG reports quarterly revenue of $10.2M, net income of $-91.2M, free cash flow of $-84.1M. Top institutional holders of CRSP by reported 13-F value include ARK Investment Management, BlackRock, Orbis Allan Gray Ltd, based on the most recent SEC filings. CRSP trades on the Nasdaq exchange and files with the SEC under CIK 1674416. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRSP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CRISPR Therapeutics AG directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1674416 →